Drug Trial Radar · NCT01755078
Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients
Last checked: Nov 20, 2026Latest source record: Aug 5, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
166
Actual
Start
Jun 2007
Primary completion
Jun 2009
Study completion Jun 2009
Sponsor
- Lead sponsor
- Chugai Pharma TaiwanIndustry
- Sponsor type
- Industry
- First posted
- Dec 21, 2012
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is designed to compare sevelamer vs. calcium-based phosphate binder in hemodialysis patients to achieve full-scale of medical care, including reduction of atherosclerotic risk factors, reduction of vascular access reconstruction rate, and pharmacoeconomic analysis.
Conditions
- Hemodialysis
- Hyperphosphatemia
- Cardiovascular Events
Interventions
Sevelamer HClDrug
Non-metal phosphate binder
Calcium-based phosphate binderDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite end-point of Ca, P, Ca*P within K/DOQI recommendationTime frame: 12 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.